

Systemic Lupus Erythematosus (SLE) Drugs Market by Drug Class (Antimalarials Drugs, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Cytotoxic and Immunosuppressive Drugs, Biologics, and Others), Mode of Delivery (Intravenous, Subcutaneous, Oral), and Region 2025-2033

https://marketpublishers.com/r/S1A327F0723CEN.html

Date: March 2025

Pages: 144

Price: US\$ 2,999.00 (Single User License)

ID: S1A327F0723CEN

# **Abstracts**

The global systemic lupus erythematosus (SLE) drugs market size reached USD 2.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.7 Billion by 2033, exhibiting a growth rate (CAGR) of 5.54% during 2025-2033. The increasing number of patients suffering from SLE, rising public awareness campaigns, and the easy availability of generic drugs represent some of the key factors driving the market.

Systemic lupus erythematosus (SLE) is an autoimmune medical condition characterized by protean clinical manifestations, multisystem inflammation (MIS), and a relapsing and remitting course (RRMS). It affects numerous parts of the body, including the skin, joints, kidneys, and brain. It is generally caused due to various genetic, environmental, and hormonal factors. Its symptoms include fatigue, joint pain and swelling, headache, rashes, hair loss, anemia, blood clotting, and fever. SLE is diagnosed by a healthcare provider using symptom assessments, physical examinations, chest X-rays, urinalysis, and blood tests. Its symptoms can be eased using anti-inflammatory drugs for joint pain and stiffness, steroid creams for rashes, corticosteroids to minimize the immune response, and antimalarial drugs for skin problems. It also uses disease-modifying drugs and targeted immune system agents for more severe cases. Besides this, it is treated using various immunosuppressive drugs that inhibit the activity of the immune system.



Systemic Lupus Erythematosus (SLE) Drugs Market Trends:

The increasing prevalence of autoimmune diseases among individuals and the rising number of patients suffering from SLE represents one of the major factors driving the demand for SLE drugs around the world. Moreover, the rising number of research and diagnostics institutes are undertaking measures and introducing public awareness campaigns to educate individuals about SLE and its possible treatments. In addition, governments and non-governmental organizations (NGOs) of numerous countries are investing in various programs to develop novel therapeutics and identify relevant drug targets for the treatment of SLE. This, coupled with the increasing financing to improve healthcare infrastructure and diagnostic technologies worldwide, is impelling the market growth. Apart from this, the easy availability of various generic drugs for relieving pain, inflammation, and stiffness associated with SLE through offline and online retail channels is favoring the market growth. They generally involve over the counter (OTC) and prescription-based nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ibuprofen (Motrin), naproxen, celecoxib (Celebrex), diclofenac (Voltaren), diflunisal (Dolobid), and piroxicam (Feldene). Furthermore, the increasing use of Hydroxychloroquine drugs is contributing to the market growth. Besides this, the growing awareness among individuals and healthcare professionals about the benefits of early diagnosis and treatment of SLE is influencing the overall sales of SLE drugs.

## Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global systemic lupus erythematosus (SLE) drugs market, along with forecasts at the global, regional, and country level from 2025-2033. Our report has categorized the market based on drug class and mode of delivery.

Drug Class Insights:

Antimalarials Drugs

Chloroquine

Hydroxychloroquine

Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)



Cytotoxic and immunosuppressive Drugs
Cyclophosphamide
Methotrexate
Mycophenolate Mofetil
Tacrolimus
Cyclosporine
Biologics
Others
The report has also provided a detailed breakup and analysis of the systemic lupus erythematosus (SLE) drugs market based on the drug class. This includes antimalarials drugs (chloroquine and hydroxycholroquine), non-steroidal anti-inflammatory drugs (NSAIDS), cytotoxic and immunosuppressive drugs (cyclophophamide, methotrexate, mycophenolate mofetil, tacrolimus, and cyclosporine), biologics, and others. According to the report, cytotoxic and immunosuppressive drugs represented the largest segment.  Mode of Delivery Insights:  Intravenous  Subcutaneous
Oral
A detailed breakup and analysis of the systemic lupus erythematosus (SLE) drugs

Regional Insights:

for the largest market share.

market based on the mode of delivery has also been provided in the report. This

includes intravenous, subcutaneous, and oral. According to the report, oral accounted



North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America



Brazil
Mexico
Others
Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America was the largest market for systemic lupus erythematosus (SLE) drugs. Some of the factors driving the North America systemic lupus erythematosus (SLE) drugs market included easy access to healthcare, the rising awareness about the benefits of early diagnosis and treatment of SLE, and the easy availability of various generic drugs.

# Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global systemic lupus erythematosus (SLE) drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AstraZeneca Plc, Aurinia Pharmaceuticals Inc., GSK plc, and ImmuPharma Plc.

Key Questions Answered in This Report

- 1. How big is the global Systemic Lupus Erythematosus (SLE) drugs market?
- 2.What is the expected growth rate of the global Systemic Lupus Erythematosus (SLE) drugs market during 2025-2033?
- 3. What are the key factors driving the global Systemic Lupus Erythematosus (SLE) drugs market?
- 4. What has been the impact of COVID-19 on the global Systemic Lupus Erythematosus (SLE) drugs market?



5. What is the breakup of the global Systemic Lupus Erythematosus (SLE) drugs market based on the drug class?

6. What is the breakup of the global Systemic Lupus Erythematosus (SLE) drugs market based on the mode of delivery?

7. What are the key regions in the global Systemic Lupus Erythematosus (SLE) drugs market?

8. Who are the key players/companies in the global Systemic Lupus Erythematosus (SLE) drugs market?



# **Contents**

#### 1 PREFACE

## 2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

## **3 EXECUTIVE SUMMARY**

## **4 INTRODUCTION**

- 4.1 Overview
- 4.2 Key Industry Trends

# 5 GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DRUGS MARKET

- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast

## **6 MARKET BREAKUP BY DRUG CLASS**

- 6.1 Antimalarials Drugs
  - 6.1.1 Market Trends
  - 6.1.2 Key Segments
    - 6.1.2.1 Chloroquine
    - 6.1.2.2 Hydroxychloroquine
  - 6.1.3 Market Forecast
- 6.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)



- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Cytotoxic and Immunosuppressive Drugs
  - 6.3.1 Market Trends
  - 6.3.2 Key Segments
    - 6.3.2.1 Cyclophosphamide
    - 6.3.2.2 Methotrexate
    - 6.3.2.3 Mycophenolate Mofetil
    - 6.3.2.4 Tacrolimus
    - 6.3.2.5 Cyclosporine
  - 6.3.3 Market Forecast
- 6.4 Biologics
  - 6.4.1 Market Trends
  - 6.4.2 Market Forecast
- 6.5 Others
  - 6.5.1 Market Trends
  - 6.5.2 Market Forecast

## 7 MARKET BREAKUP BY MODE OF DELIVERY

- 7.1 Intravenous
  - 7.1.1 Market Trends
  - 7.1.2 Market Forecast
- 7.2 Subcutaneous
  - 7.2.1 Market Trends
  - 7.2.2 Market Forecast
- 7.3 Oral
  - 7.3.1 Market Trends
  - 7.3.2 Market Forecast

## **8 MARKET BREAKUP BY REGION**

- 8.1 North America
  - 8.1.1 United States
    - 8.1.1.1 Market Trends
    - 8.1.1.2 Market Forecast
  - 8.1.2 Canada
    - 8.1.2.1 Market Trends
    - 8.1.2.2 Market Forecast



- 8.2 Asia-Pacific
  - 8.2.1 China
    - 8.2.1.1 Market Trends
    - 8.2.1.2 Market Forecast
  - 8.2.2 Japan
    - 8.2.2.1 Market Trends
    - 8.2.2.2 Market Forecast
  - 8.2.3 India
    - 8.2.3.1 Market Trends
    - 8.2.3.2 Market Forecast
  - 8.2.4 South Korea
    - 8.2.4.1 Market Trends
    - 8.2.4.2 Market Forecast
  - 8.2.5 Australia
    - 8.2.5.1 Market Trends
    - 8.2.5.2 Market Forecast
  - 8.2.6 Indonesia
    - 8.2.6.1 Market Trends
    - 8.2.6.2 Market Forecast
  - 8.2.7 Others
    - 8.2.7.1 Market Trends
    - 8.2.7.2 Market Forecast
- 8.3 Europe
  - 8.3.1 Germany
    - 8.3.1.1 Market Trends
    - 8.3.1.2 Market Forecast
  - 8.3.2 France
    - 8.3.2.1 Market Trends
    - 8.3.2.2 Market Forecast
  - 8.3.3 United Kingdom
    - 8.3.3.1 Market Trends
    - 8.3.3.2 Market Forecast
  - 8.3.4 Italy
    - 8.3.4.1 Market Trends
    - 8.3.4.2 Market Forecast
  - 8.3.5 Spain
    - 8.3.5.1 Market Trends
    - 8.3.5.2 Market Forecast
  - 8.3.6 Russia



- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
  - 8.3.7.1 Market Trends
  - 8.3.7.2 Market Forecast
- 8.4 Latin America
  - 8.4.1 Brazil
    - 8.4.1.1 Market Trends
    - 8.4.1.2 Market Forecast
  - 8.4.2 Mexico
    - 8.4.2.1 Market Trends
    - 8.4.2.2 Market Forecast
  - 8.4.3 Others
    - 8.4.3.1 Market Trends
    - 8.4.3.2 Market Forecast
- 8.5 Middle East and Africa
  - 8.5.1 Market Trends
  - 8.5.2 Market Breakup by Country
  - 8.5.3 Market Forecast

# 9 DRIVERS, RESTRAINTS, AND OPPORTUNITIES

- 9.1 Overview
- 9.2 Drivers
- 9.3 Restraints
- 9.4 Opportunities

## **10 VALUE CHAIN ANALYSIS**

## 11 PORTERS FIVE FORCES ANALYSIS

- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes

## 12 PRICE ANALYSIS



## 13 COMPETITIVE LANDSCAPE

- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
  - 13.3.1 AstraZeneca Plc
    - 13.3.1.1 Company Overview
    - 13.3.1.2 Product Portfolio
    - 13.3.1.3 Financials
  - 13.3.1.4 SWOT Analysis
  - 13.3.2 Aurinia Pharmaceuticals Inc.
    - 13.3.2.1 Company Overview
    - 13.3.2.2 Product Portfolio
    - 13.3.2.3 Financials
  - 13.3.3 GSK plc
    - 13.3.3.1 Company Overview
    - 13.3.3.2 Product Portfolio
    - 13.3.3.3 Financials
  - 13.3.3.4 SWOT Analysis
  - 13.3.4 ImmuPharma Plc
    - 13.3.4.1 Company Overview
    - 13.3.4.2 Product Portfolio
    - 13.3.4.3 Financials
    - 13.3.4.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.



# **List Of Tables**

## LIST OF TABLES

Table 1: Global: Systemic Lupus Erythematosus Drugs Market: Key Industry Highlights, 2024 & 2033

Table 2: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033

Table 3: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Breakup by Mode of Delivery (in Million USD), 2025-2033

Table 4: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033

Table 5: Global: Systemic Lupus Erythematosus Drugs Market: Competitive Structure

Table 6: Global: Systemic Lupus Erythematosus Drugs Market: Key Players



# **List Of Figures**

## LIST OF FIGURES

?Figure 1: Global: Systemic Lupus Erythematosus Drugs Market: Major Drivers and Challenges

Figure 2: Global: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Billion USD), 2019-2024

Figure 3: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033

Figure 4: Global: Systemic Lupus Erythematosus Drugs Market: Breakup by Drug Class (in %), 2024

Figure 5: Global: Systemic Lupus Erythematosus Drugs Market: Breakup by Mode of Delivery (in %), 2024

Figure 6: Global: Systemic Lupus Erythematosus Drugs Market: Breakup by Region (in %), 2024

Figure 7: Global: Systemic Lupus Erythematosus Drugs (Antimalarials Drugs) Market: Sales Value (in Million USD), 2019 & 2024

Figure 8: Global: Systemic Lupus Erythematosus Drugs (Antimalarials Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033

Figure 9: Global: Systemic Lupus Erythematosus Drugs (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)) Market: Sales Value (in Million USD), 2019 & 2024 Figure 10: Global: Systemic Lupus Erythematosus Drugs (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)) Market Forecast: Sales Value (in Million USD), 2025-2033

Figure 11: Global: Systemic Lupus Erythematosus Drugs (Cytotoxic and Immunosuppressive Drugs) Market: Sales Value (in Million USD), 2019 & 2024

Figure 12: Global: Systemic Lupus Erythematosus Drugs (Cytotoxic and

Immunosuppressive Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033

Figure 13: Global: Systemic Lupus Erythematosus Drugs (Biologics) Market: Sales Value (in Million USD), 2019 & 2024

Figure 14: Global: Systemic Lupus Erythematosus Drugs (Biologics) Market Forecast: Sales Value (in Million USD), 2025-2033

Figure 15: Global: Systemic Lupus Erythematosus Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024

Figure 16: Global: Systemic Lupus Erythematosus Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033

Figure 17: Global: Systemic Lupus Erythematosus Drugs (Intravenous) Market: Sales Value (in Million USD), 2019 & 2024



Figure 18: Global: Systemic Lupus Erythematosus Drugs (Intravenous) Market

Forecast: Sales Value (in Million USD), 2025-2033

Figure 19: Global: Systemic Lupus Erythematosus Drugs (Subcutaneous) Market: Sales

Value (in Million USD), 2019 & 2024

Figure 20: Global: Systemic Lupus Erythematosus Drugs (Subcutaneous) Market

Forecast: Sales Value (in Million USD), 2025-2033

Figure 21: Global: Systemic Lupus Erythematosus Drugs (Oral) Market: Sales Value (in

Million USD), 2019 & 2024

Figure 22: Global: Systemic Lupus Erythematosus Drugs (Oral) Market Forecast: Sales

Value (in Million USD), 2025-2033

Figure 23: North America: Systemic Lupus Erythematosus Drugs Market: Sales Value

(in Million USD), 2019 & 2024

Figure 24: North America: Systemic Lupus Erythematosus Drugs Market Forecast:

Sales Value (in Million USD), 2025-2033

Figure 25: United States: Systemic Lupus Erythematosus Drugs Market: Sales Value (in

Million USD), 2019 & 2024

Figure 26: United States: Systemic Lupus Erythematosus Drugs Market Forecast: Sales

Value (in Million USD), 2025-2033

Figure 27: Canada: Systemic Lupus Erythematosus Drugs Market: Sales Value (in

Million USD), 2019 & 2024

Figure 28: Canada: Systemic Lupus Erythematosus Drugs Market Forecast: Sales

Value (in Million USD), 2025-2033

Figure 29: Asia-Pacific: Systemic Lupus Erythematosus Drugs Market: Sales Value (in

Million USD), 2019 & 2024

Figure 30: Asia-Pacific: Systemic Lupus Erythematosus Drugs Market Forecast: Sales

Value (in Million USD), 2025-2033

Figure 31: China: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million

USD), 2019 & 2024

Figure 32: China: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value

(in Million USD), 2025-2033

Figure 33: Japan: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million

USD), 2019 & 2024

Figure 34: Japan: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value

(in Million USD), 2025-2033

Figure 35: India: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million

USD), 2019 & 2024

Figure 36: India: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value

(in Million USD), 2025-2033

Figure 37: South Korea: Systemic Lupus Erythematosus Drugs Market: Sales Value (in



Million USD), 2019 & 2024

Figure 38: South Korea: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2025-2033

Figure 39: Australia: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2019 & 2024

Figure 40: Australia: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2025-2033

Figure 41: Indonesia: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2019 & 2024

Figure 42: Indonesia: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2025-2033

Figure 43: Others: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2019 & 2024

Figure 44: Others: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2025-2033

Figure 45: Europe: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2019 & 2024

Figure 46: Europe: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2025-2033

Figure 47: Germany: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2019 & 2024

Figure 48: Germany: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2025-2033

Figure 49: France: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2019 & 2024

Figure 50: France: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2025-2033

Figure 51: United Kingdom: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2019 & 2024

Figure 52: United Kingdom: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2025-2033

Figure 53: Italy: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2019 & 2024

Figure 54: Italy: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2025-2033

Figure 55: Spain: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2019 & 2024

Figure 56: Spain: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2025-2033



Figure 57: Russia: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2019 & 2024

Figure 58: Russia: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2025-2033

Figure 59: Others: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2019 & 2024

Figure 60: Others: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2025-2033

Figure 61: Latin America: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2019 & 2024

Figure 62: Latin America: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2025-2033

Figure 63: Brazil: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2019 & 2024

Figure 64: Brazil: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2025-2033

Figure 65: Mexico: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2019 & 2024

Figure 66: Mexico: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2025-2033

Figure 67: Others: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2019 & 2024

Figure 68: Others: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2025-2033

Figure 69: Middle East and Africa: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million USD), 2019 & 2024

Figure 70: Middle East and Africa: Systemic Lupus Erythematosus Drugs Market: Breakup by Country (in %), 2024

Figure 71: Middle East and Africa: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million USD), 2025-2033

Figure 72: Global: Systemic Lupus Erythematosus Drugs Industry: Drivers, Restraints, and Opportunities

Figure 73: Global: Systemic Lupus Erythematosus Drugs Industry: Value Chain Analysis

Figure 74: Global: Systemic Lupus Erythematosus Drugs Industry: Porter's Five Forces Analysis



# I would like to order

Product name: Systemic Lupus Erythematosus (SLE) Drugs Market by Drug Class (Antimalarials Drugs,

Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Cytotoxic and Immunosuppressive Drugs, Biologics, and Others), Mode of Delivery (Intravenous, Subcutaneous, Oral), and

Region 2025-2033

Product link: https://marketpublishers.com/r/S1A327F0723CEN.html

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/S1A327F0723CEN.html">https://marketpublishers.com/r/S1A327F0723CEN.html</a>